Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology
17 nov. 2023 07h00 HE
|
Medicenna Therapeutics Corp.
Single treatment of bizaxofusp doubled mOS (14.5 months vs. 7.2 months) irrespective of IL4R expression (high or low) compared to patients treated in the external control arm Survival for...
Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights
14 nov. 2023 08h30 HE
|
Medicenna Therapeutics Corp.
Cash runway extended through multiple data readouts and into Q1 of calendar 2025 MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1...
Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting
09 nov. 2023 08h56 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the...
Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
06 nov. 2023 07h00 HE
|
Medicenna Therapeutics Corp.
Please include the distribution list on file.
Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
03 nov. 2023 12h00 HE
|
Medicenna Therapeutics Corp.
Company’s T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics ...
Medicenna Announces Nasdaq Delisting and Cutback of Management Team
27 oct. 2023 07h55 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors
25 oct. 2023 07h00 HE
|
Medicenna Therapeutics Corp.
New data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting on November 4, 2023 Company expects to...
Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)
24 oct. 2023 07h15 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
10 oct. 2023 07h07 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy
03 oct. 2023 07h00 HE
|
Medicenna Therapeutics Corp.
MDNA223 is a bifunctional Superkine designed to activate cancer-killing immune cells via the IL-2 receptor while simultaneously preventing their exhaustion by blocking PD-1 signallingMDNA223...